{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:49:00Z","timestamp":1789505340983,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41440-025-02388-5","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T07:20:58Z","timestamp":1759303258000},"page":"499-507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["SGLT2 inhibitor requires co-administration with diuretics to effectively reduce interstitial fluid retention: the DAPA-BODY trial"],"prefix":"10.1038","volume":"49","author":[{"given":"Takahiro","family":"Masuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Asakura-Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Misawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Morinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Akimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"2388_CR1","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1093\/ndt\/gfae060","volume":"39","author":"V Vallon","year":"2024","unstructured":"Vallon V. How can inhibition of glucose and sodium transport in the early proximal tubule protect the cardiorenal system? Nephrol Dial Transpl. 2024;39:1565\u201373.","journal-title":"Nephrol Dial Transpl"},{"key":"2388_CR2","doi-asserted-by":"publisher","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","volume":"306","author":"T Rieg","year":"2014","unstructured":"Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Ren Physiol. 2014;306:F188\u201393.","journal-title":"Am J Physiol Ren Physiol"},{"key":"2388_CR3","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies G, Consortium SiM-AC-RT.","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies G, Consortium SiM-AC-RT. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788\u2013801.","journal-title":"Lancet"},{"key":"2388_CR4","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41440-023-01220-2","volume":"46","author":"T Masuda","year":"2023","unstructured":"Masuda T, Nagata D. Fluid homeostasis induced by sodium-glucose cotransporter 2 inhibitors: novel insight for better cardio-renal outcomes in chronic kidney disease. Hypertens Res. 2023;46:1195\u2013201.","journal-title":"Hypertens Res"},{"key":"2388_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/dom.13126","volume":"20","author":"KM Hallow","year":"2018","unstructured":"Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diab Obes Metab. 2018;20:479\u201387.","journal-title":"Diab Obes Metab"},{"key":"2388_CR6","doi-asserted-by":"crossref","unstructured":"Asakura-Kinoshita M, Masuda T, Oka K, Ohara K, Miura M, Morinari M, et al. Sodium-glucose cotransporter 2 inhibitor combined with conventional diuretics ameliorate body fluid retention without excessive plasma volume reduction. Diagnostics. 2024;14.","DOI":"10.3390\/diagnostics14111194"},{"key":"2388_CR7","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1038\/s41440-024-01893-3","volume":"47","author":"T Masuda","year":"2024","unstructured":"Masuda T, Yoshida M, Onaka T, Nagata D. Water and sodium conservation response induced by SGLT2 inhibitor ipragliflozin in Dahl salt-sensitive hypertensive rats. Hypertens Res. 2024;47:3173\u201381.","journal-title":"Hypertens Res"},{"key":"2388_CR8","doi-asserted-by":"publisher","first-page":"F653","DOI":"10.1152\/ajprenal.00143.2018","volume":"315","author":"T Masuda","year":"2018","unstructured":"Masuda T, Watanabe Y, Fukuda K, Watanabe M, Onishi A, Ohara K, et al. Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat. Am J Physiol Ren Physiol. 2018;315:F653\u201364.","journal-title":"Am J Physiol Ren Physiol"},{"key":"2388_CR9","first-page":"1","volume":"1","author":"T Masuda","year":"2017","unstructured":"Masuda T, Ohara K, Murakami T, Imai T, Nakagawa S, Okada M, et al. Sodium-glucose cotransporter 2 inhibition with dapagliflozin ameliorates extracellular volume expansion in diabetic kidney disease patients. POJ Diab Obes. 2017;1:1\u20138.","journal-title":"POJ Diab Obes"},{"key":"2388_CR10","doi-asserted-by":"publisher","first-page":"F361","DOI":"10.1152\/ajprenal.00070.2022","volume":"323","author":"T Masuda","year":"2022","unstructured":"Masuda T, Ohara K, Vallon V, Nagata D. SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats. Am J Physiol Ren Physiol. 2022;323:F361\u201369.","journal-title":"Am J Physiol Ren Physiol"},{"key":"2388_CR11","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14360","volume":"8","author":"T Masuda","year":"2020","unstructured":"Masuda T, Muto S, Fukuda K, Watanabe M, Ohara K, Koepsell H, et al. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume. Physiol Rep. 2020;8:e14360.","journal-title":"Physiol Rep"},{"key":"2388_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1287066","volume":"10","author":"K Oka","year":"2023","unstructured":"Oka K, Masuda T, Ohara K, Miura M, Morinari M, Misawa K, et al. Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY Trial. Front Med (Lausanne). 2023;10:1287066.","journal-title":"Front Med (Lausanne)"},{"key":"2388_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13098-020-00545-z","volume":"12","author":"K Ohara","year":"2020","unstructured":"Ohara K, Masuda T, Morinari M, Okada M, Miki A, Nakagawa S, et al. The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease. Diabetol Metab Syndr. 2020;12:37.","journal-title":"Diabetol Metab Syndr"},{"key":"2388_CR14","doi-asserted-by":"crossref","unstructured":"Hung SC, Lai YS, Kuo KL, Tarng DC. Volume overload and adverse outcomes in chronic kidney disease: clinical observational and animal studies. J Am Heart Assoc 2015;4.","DOI":"10.1161\/JAHA.115.001918"},{"key":"2388_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/1471-2369-15-189","volume":"15","author":"R Tai","year":"2014","unstructured":"Tai R, Ohashi Y, Mizuiri S, Aikawa A, Sakai K. Association between ratio of measured extracellular volume to expected body fluid volume and renal outcomes in patients with chronic kidney disease: a retrospective single-center cohort study. BMC Nephrol. 2014;15:189.","journal-title":"BMC Nephrol"},{"key":"2388_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1053\/j.ajkd.2013.06.011","volume":"63","author":"YC Tsai","year":"2014","unstructured":"Tsai YC, Tsai JC, Chen SC, Chiu YW, Hwang SJ, Hung CC, et al. Association of fluid overload with kidney disease progression in advanced CKD: a prospective cohort study. Am J Kidney Dis. 2014;63:68\u201375.","journal-title":"Am J Kidney Dis"},{"key":"2388_CR17","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1210\/jc.2019-01049","volume":"104","author":"M Kanbay","year":"2019","unstructured":"Kanbay M, Yilmaz S, Dincer N, Ortiz A, Sag AA, Covic A, et al. Antidiuretic hormone and serum osmolarity physiology and related outcomes: What Is Old, What Is New, and What Is Unknown? J Clin Endocrinol Metab. 2019;104:5406\u201320.","journal-title":"J Clin Endocrinol Metab"},{"key":"2388_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","volume":"52","author":"NG Morgenthaler","year":"2006","unstructured":"Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52:112\u20139.","journal-title":"Clin Chem"},{"key":"2388_CR19","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.ekir.2022.02.023","volume":"7","author":"RA Scholtes","year":"2022","unstructured":"Scholtes RA, Muskiet MHA, van Baar MJB, Hesp AC, Greasley PJ, Hammarstedt A, et al. The adaptive renal response for volume homeostasis during 2 weeks of dapagliflozin treatment in people with type 2 diabetes and preserved renal function on a sodium-controlled diet. Kidney Int Rep. 2022;7:1084\u201392.","journal-title":"Kidney Int Rep"},{"key":"2388_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1098404","volume":"17","author":"AM Berton","year":"2023","unstructured":"Berton AM, Parasiliti-Caprino M, Prencipe N, Bioletto F, Lopez C, Bona C, et al. Copeptin adaptive response to SGLT2 inhibitors in patients with type 2 diabetes mellitus: The GliRACo study. Front Neurosci. 2023;17:1098404.","journal-title":"Front Neurosci"},{"key":"2388_CR21","doi-asserted-by":"publisher","first-page":"F958","DOI":"10.1152\/ajprenal.00476.2015","volume":"310","author":"X Huang","year":"2016","unstructured":"Huang X, Dorhout Mees E, Vos P, Hamza S, Braam B. Everything we always wanted to know about furosemide but were afraid to ask. Am J Physiol Ren Physiol. 2016;310:F958\u201371.","journal-title":"Am J Physiol Ren Physiol"},{"key":"2388_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ekir.2018.09.011","volume":"4","author":"SK Channavajjhala","year":"2019","unstructured":"Channavajjhala SK, Bramley R, Peltz T, Oosthuyzen W, Jia W, Kinnear S, et al. Urinary extracellular vesicle protein profiling and endogenous lithium clearance support excessive renal sodium wasting and water reabsorption in thiazide-induced hyponatremia. Kidney Int Rep. 2019;4:139\u201347.","journal-title":"Kidney Int Rep"},{"key":"2388_CR23","unstructured":"InBody Co., Ltd. InBody S10 User\u2019s manual. 2015."},{"key":"2388_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/MAT.0000000000000619","volume":"64","author":"CR Kim","year":"2018","unstructured":"Kim CR, Shin JH, Hwang JH, Kim SH. Monitoring volume status using bioelectrical impedance analysis in chronic hemodialysis patients. ASAIO J. 2018;64:245\u201352.","journal-title":"ASAIO J"},{"key":"2388_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2021.111567","volume":"96","author":"K Zheng","year":"2022","unstructured":"Zheng K, Lu J, Liu X, Ji W, Liu P, Cui J, et al. The clinical application value of the extracellular-water-to-total-body-water ratio obtained by bioelectrical impedance analysis in people with advanced cancer. Nutrition. 2022;96:111567.","journal-title":"Nutrition"},{"key":"2388_CR26","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"2388_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Toto RD, Stefansson BV, Jongs N, Chertow GM, Greene T, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100:215\u201324.","journal-title":"Kidney Int"},{"key":"2388_CR28","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"2388_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03725-z","volume":"25","author":"AH Flannery","year":"2021","unstructured":"Flannery AH, Ortiz-Soriano V, Li X, Gianella FG, Toto RD, Moe OW, et al. Serum renin and major adverse kidney events in critically ill patients: a multicenter prospective study. Crit Care. 2021;25:294.","journal-title":"Crit Care"},{"key":"2388_CR30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/ajh\/hpaa169","volume":"34","author":"M Rieder","year":"2021","unstructured":"Rieder M, Wirth L, Pollmeier L, Jeserich M, Goller I, Baldus N, et al. Serum ACE2, angiotensin II, and aldosterone levels are unchanged in patients with COVID-19. Am J Hypertens. 2021;34:278\u201381.","journal-title":"Am J Hypertens"},{"key":"2388_CR31","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1172\/JCI102501","volume":"30","author":"MB Strauss","year":"1951","unstructured":"Strauss MB, Davis RK, Rosenbaum JD, Rossmeisl EC. Water diuresis produced during recumbency by the intravenous infusion of isotonic saline solution. J Clin Invest. 1951;30:862\u20138.","journal-title":"J Clin Invest"},{"key":"2388_CR32","first-page":"M597","volume":"36","author":"AA Kaplan","year":"1990","unstructured":"Kaplan AA. A simple and accurate method for prescribing plasma exchange. ASAIO Trans. 1990;36:M597\u201399.","journal-title":"ASAIO Trans"},{"key":"2388_CR33","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1182\/blood.V33.5.649.649","volume":"33","author":"JA Retzlaff","year":"1969","unstructured":"Retzlaff JA, Tauxe WN, Kiely JM, Stroebel CF. Erythrocyte volume, plasma volume, and lean body mass in adult men and women. Blood. 1969;33:649\u201361.","journal-title":"Blood"},{"key":"2388_CR34","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/nep.13552","volume":"24","author":"K Ohara","year":"2019","unstructured":"Ohara K, Masuda T, Murakami T, Imai T, Yoshizawa H, Nakagawa S, et al. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: a comparison study with furosemide and tolvaptan. Nephrology. 2019;24:904\u201311.","journal-title":"Nephrology"},{"key":"2388_CR35","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s11255-019-02180-8","volume":"51","author":"T Masuda","year":"2019","unstructured":"Masuda T, Ohara K, Nagayama I, Matsuoka R, Murakami T, Nakagawa S, et al. Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients. Int Urol Nephrol. 2019;51:1623\u20139.","journal-title":"Int Urol Nephrol"},{"key":"2388_CR36","doi-asserted-by":"crossref","unstructured":"Durante W, Behnammanesh G, Peyton KJ. Effects of sodium-glucose co-transporter 2 inhibitors on vascular cell function and arterial remodeling. Int J Mol Sci 2021; 22.","DOI":"10.3390\/ijms22168786"},{"key":"2388_CR37","first-page":"169","volume":"5","author":"LY Herat","year":"2020","unstructured":"Herat LY, Magno AL, Rudnicka C, Hricova J, Carnagarin R, Ward NC, et al. SGLT2 inhibitor-induced sympathoinhibition. A Nov Mechanism Cardiorenal Prot JACC Basic Transl Sci. 2020;5:169\u201379.","journal-title":"A Nov Mechanism Cardiorenal Prot JACC Basic Transl Sci"},{"key":"2388_CR38","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.2169\/internalmedicine.0701-17","volume":"57","author":"S Sugiyama","year":"2018","unstructured":"Sugiyama S, Jinnouchi H, Kurinami N, Hieshima K, Yoshida A, Jinnouchi K, et al. The SGLT2 inhibitor dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus. Intern Med. 2018;57:2147\u201356.","journal-title":"Intern Med"},{"key":"2388_CR39","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jacc.2024.02.028","volume":"83","author":"M Packer","year":"2024","unstructured":"Packer M. SGLT2 inhibition: neither a diuretic nor a natriuretic. J Am Coll Cardiol. 2024;83:1399\u2013402.","journal-title":"J Am Coll Cardiol"},{"key":"2388_CR40","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jacc.2024.02.020","volume":"83","author":"A Marton","year":"2024","unstructured":"Marton A, Saffari SE, Rauh M, Sun RN, Nagel AM, Linz P, et al. Water conservation overrides osmotic diuresis during SGLT2 inhibition in patients with heart failure. J Am Coll Cardiol. 2024;83:1386\u201398.","journal-title":"J Am Coll Cardiol"},{"key":"2388_CR41","doi-asserted-by":"publisher","first-page":"F712","DOI":"10.1152\/ajprenal.00264.2020","volume":"319","author":"A Onishi","year":"2020","unstructured":"Onishi A, Fu Y, Patel R, Darshi M, Crespo-Masip M, Huang W, et al. A role for tubular Na(+)\/H(+) exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin. Am J Physiol Ren Physiol. 2020;319:F712\u201328.","journal-title":"Am J Physiol Ren Physiol"},{"key":"2388_CR42","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/s41440-024-01744-1","volume":"47","author":"K Kario","year":"2024","unstructured":"Kario K, Hoshide S, Mogi M. Hypertension treatment up-date on World Hypertension Day 2024: current status and future prospects in Asia. Hypertens Res. 2024;47:1763\u20135.","journal-title":"Hypertens Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02388-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:03:07Z","timestamp":1772121787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02388-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2388"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02388-5","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}